If enacted, HB 7693 would specifically benefit pharmaceutical companies engaged in the research and development of orphan drugs. With the extension of exclusivity periods, these companies would potentially have greater economic protections and incentives to invest in developing treatments for rare diseases, which may otherwise be neglected due to smaller market sizes. This could lead to an increase in the availability of treatments for patients suffering from rare conditions, improving public health outcomes.
Summary
House Bill 7693, also known as 'Leo's Law', aims to mitigate the adverse effects of the COVID-19 pandemic on the development incentives for orphan drugs under the Federal Food, Drug, and Cosmetic Act. The bill proposes to extend various exclusivity periods for covered orphan drugs by an additional 180 days. This extension is significant as it provides drug manufacturers with more time to develop medications for rare diseases during an unprecedented public health crisis.
Contention
The bill may face some contention regarding its effectiveness and timing. Critics might argue that extending exclusivity periods could delay the arrival of affordable medications to the market, potentially causing harm to patients who rely on these treatments. Furthermore, concerns may arise regarding the balance between incentivizing drug development and ensuring that the drugs remain accessible and affordable once they are developed. Overall, the dialogue around this bill will likely focus on finding the right balance between incentivizing innovation in the pharmaceutical industry and protecting patient access to necessary medications.
Domestic Security Using Production Partnerships and Lessons from Yesterday Act of 2025 or the Domestic SUPPLY Act of 2025This bill establishes a program and sets out other requirements to promote domestic manufacturing of personal protective equipment (PPE) to address infectious diseases and other public health emergencies.Specifically, the Department of Health and Human Services (HHS) must establish a program to enter into purchasing agreements with eligible domestic manufacturers for PPE to prepare for and respond to public health emergencies. To be eligible, manufacturers must be majority owned and operated by U.S. citizens and must manufacture a majority of their contracted products domestically, with 100% of products manufactured domestically by 2028. HHS must coordinate with the Department of Defense and the Department of Homeland Security on this program.In addition, the federal government must only procure, subject to limited exceptions, clothing or equipment that is produced domestically to prevent the transmission of an infectious disease. If using federal funds, states or localities must also procure such items domestically.Further, the bill requires HHS to submit to Congress a report about changes to federal requirements for PPE since the beginning of the COVID-19 pandemic and the impact of those changes on health care workers who cared for patients in 2020 and 2021.